In this context, the MYCN-specific antigene oligonucleotide BGA002 proved to have high specificity and efficacy in MYCN-related NB [35,36], thus also representing a novel precision medicine approach for MYCN-related SCLC treatment. Here, MYCN is linked to neuroblastoma.